Expression And Clinical Significance Of Galectin-1, VEGF And CD31in Gastric Carcinoma

Backgroud&Aim:Galectin-1as a member of Galectin family was the first to be discovered, and closely related to tumor immunosuppression, tumor angiogenesis and tumor cell proliferation, invasion and metastasis. This part of the study was to detect Galectin-1,VEGF and CD31expression in gastric cancer tissue specimens in gastric cancer, to explore the possible mechanism of angiogenesis, invasion and metastasis of gastric cancer and their relationship with clinicopathologie parameters and prognostic.Methods:1,A retrospective analysis of62cases clinical data of patients with surgically resected gastric tumors in the clinical college of Yangzhou University from January2008to December2008.2,The relevant Galectin-1,VEGF and CD31expression of tumor specimens were detected by immunohistochemical staining. SPSS described the survival of patients with stomach cancer, and clinical data was statistical analyzed.Results:The clinical data of62cases of gastric cancer were analyzed, Galectin-1expression was associated with tumor size, tumor location, depth of invasion, lymph node metastasis and TNM stage, with lower histological differentiation grade and gradually increased (strong/weak expression were:well4/8cases, differentiated9/13cases, poorly differentiated21/8cases, p <0.05); VEGF expression was associated with depth of invasion, lymph node metastasis, and TNM stage, with the organization credits reduce gradually increased degree (strong/weak expression was:well4/8cases, differentiated9/12cases, poorly differentiated24/5cases, p <0.01) Galectin-1and VEGF expression was positively correlated (p=0.014); CD31expression and depth of invasion, lymph node metastasis, and TNM stage are closely related, and with lower histological differentiation grade and gradually increased (strong/weak expression was: well3/4cases, differentiated7/14cases, poorly differentiated23/6cases, p<0.01); Galectin-1expression and CD31expression was positively correlated (p=0.000) and the median survival of patients with high expression of Galectin-1and low expression has significant differences.(P <0.01), the median survival time was29.7months and40.5months. Patients with high VEGF expression and low expression median survival with significant differences (P<0.01), the median survival time was32.5months and48.6months. Patients with high expression of CD31and low expression of median survival with significant differences (P<0.01), the median survival time was31.3months and45.1months. Patients Galectin-1and VEGF expression was significantly higher than the prognosis of patients with low Galectin-1and VEGF expression difference in median survival between the two groups with a significant difference (P<0.01), the median survival time was19.1months and58.6months. Patients Galectin-1and CD31expression was significantly higher than the prognosis of patients with low Galectin-1and CD31expression is poor, with a median survival of a significant difference (P<0.01) between the two groups, the median survival time was21.5months and52.8months. Galectin-1VEGF in gastric cancer patients with high expression of CD31and poor prognosis,5-year recurrence rates were88.3%,91.9%,87.9%.5-year recurrence rate of Galectin-1VEGF and CD3expression are:75%,68%,72.4%, there are significant differences between the groups differences (P<0.05). Conclusion:1. Galectin-1, VEGF and CD31is closely related to clinical data and prognosis in patients with gastric cancer2. Galectin-1and VEGF, Galectin-1and CD31expression in gastric cancer between statistical correlation may suggest a carcinogenic effect Galectin-1gene is associated with tumor angiogenesis, invasion and metastasis of gastric cancer prompted Galectin-1, VEGF and CD31were closely related, suggesting that not only the three indexes were related to gastric cancer invasion and metastasis, but also can be used as the prediction indicators of gastric cancer angiogenesis, metastasis, recurrence and judging prognosis.